Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.36 |
| ▸ | POLRMT | O00411 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18636432 | 0.90 | TMPRSS2 (0.36) | TMPRSS2POLRMTTNK2 | |
| SCHEMBL18636477 | 0.84 | TMPRSS2 (0.45) | TMPRSS2POLRMTTNK2PRMT5WDR77 | |
| SCHEMBL10153929 | 0.83 | TMPRSS2 (0.44) | TMPRSS2POLRMT | |
| SCHEMBL24606306 | 0.83 | TMPRSS2 (0.41) | TMPRSS2POLRMT | |
| SCHEMBL20078677 | 0.82 | TMPRSS2 (0.40) | TMPRSS2POLRMT | |
| SCHEMBL24789693 | 0.80 | POLRMT (0.38) | TMPRSS2POLRMT | |
| SCHEMBL10082720 | 0.80 | BACE1 (0.34) | TMPRSS2TNK2 | |
| SCHEMBL26004157 | 0.80 | TMPRSS2 (0.41) | TMPRSS2POLRMTTNK2PRMT5WDR77 | |
| SCHEMBL24074599 | 0.80 | POLRMT (0.49) | TMPRSS2POLRMT | |
| SCHEMBL26003209 | 0.79 | TMPRSS2 (0.37) | TMPRSS2POLRMTPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11266666-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210052613-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052613-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | TMPRSS2 1951/4885POLRMT 104/4885TNK2 2705/4885 |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | TMPRSS2 1951/4885POLRMT 104/4885TNK2 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.